Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TO-O-1007 (high-dose): Participants will receive two TO-O-1007 implants administered by intravitreal injection into the study eye.”In the company’s words, NCT07668804 on ClinicalTrials.gov
- Main trialPhase 1/2
- “This study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of TO-O-1007, a biodegradable sustained-release intravitreal implant, for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). A long-acting intravitreal implant providing sustained delivery of API over 6 months may slow the progression of GA lesions while reducing treatment burden associated with frequent intravitreal injections. TO-O-1007 may offer a convenient treatment option with the potential to preserve retinal structure and visual function while…”In the company’s words, NCT07668804 on ClinicalTrials.gov
Other drugs for Geographic Atrophy Due to Age-Related Macular Degeneration
- TinlarebantBelite Bio, Inc · Phase 3
- VonaprumentAnnexon, Inc. · Phase 3
- CemdisiranRegeneron · Phase 3
- PozelimabRegeneron · Phase 3
- BevemipretideMighty Therapeutics Inc. · Phase 2/3
- JNJ-81201887Johnson & Johnson (Janssen) · Phase 2/3
Coming up1
- 31 Aug 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 31 Aug 2027 | A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026